EN DE
Watch Rubicon Organics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Rubicon Organics Inc (ROMJ) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Rubicon Organics Inc stock C$0.39, price C$0.43, that is 9.1% below the price, quality 36 out of 100. Rating: fairly valued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CA · ISIN CA78112W1005

RO Rubicon Organics Inc logo Thin data Nov 7, 2026

Rubicon Organics Inc

ROMJ · V
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Revenue last quarter +23% vs. a year ago.
Fair value C$0.3910 · Fairly valued
Mixed Growth (revenue 5y +44.7 %/yr in CAD)
Loss over the last twelve months · -2.7% net margin (TTM) · fiscal year 2025 1.8%
Quality 36/100
Negative free cash flow
Trails peers (4/11)
Narrow moat 14/100 · thin data
Thin data
⚠ Dilution
Watch Rubicon Organics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$2.60 C$0.3000 Fair Value C$0.3910 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range C$0.3000 – C$2.60 · fair‑value band C$0.3145 – C$0.3995 · the C$0.4300 price screens above the C$0.3910 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Rubicon Organics in your weekly email

Every Wednesday you see whether Rubicon Organics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Rubicon Organics Inc., together with its subsidiaries, engages in the production, processing, and sale of organic cannabis for the recreational and medical-use markets in Canada and internationally.

Show moreShow less

The company offers cannabis products in dried flower, pre-rolls, concentrates, gummies, capsules, edibles, vapes, topicals, relief sticks, and oils. It sells its products under the Simply Bare Organic, 1964 Supply Co, Homestead Cannabis Supply, and Wildflower brand names.

The company was formerly known as West Coast Land Corporation and changed its name to Rubicon Organics Inc. in May 2018. Rubicon Organics Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

Stock analysis

Rubicon Organics Inc (ROMJ) currently trades at C$0.4300, while our model-based Fair Value estimate is C$0.3910, so the stock looks roughly fairly valued today (gap 10.0%).

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of C$0.5200 per share, and 5 of the 14 models we run sit above the C$0.4300 price.

Bear case: the Asset-Based group reads lowest at C$0.1900, and 9 of the 14 models stay below the price. Data coverage for this calculation is low.

Scenario range: C$0.3145 (bear) to C$0.3995 (bull), the price of C$0.4300 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Rubicon Organics Inc reported revenue of C$59.5M in FY2025 versus C$22.6M in FY2021, a compound +27.3%/yr. Reported net income was C$1.1M in FY2025.

Key figures

Market cap C$28.9M (≈ $20.5M) Micro · P/S ratio 0.41 · EPS (TTM) C$−0.0200 · Net margin −2.7% · Return on equity −4.1% · Return on assets (EBIT) −6.1% (5-year average) · Operating margin 3.7% · Revenue (TTM) C$64.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).

What moves the price

The share trades about 27% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −9%, ROMJ screens cheaper than that median.

Fair Value models

Bear C$0.3145 Fair Value C$0.3910 Bull C$0.3995
Price C$0.4300 · Downside -9.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income C$0.4600 C$0.4600 C$0.4700 76
ROIC Compounder C$0.1200 C$0.1600 C$0.2000 72
EPV C$0.1200 C$0.1600 C$0.2000 71
All 14 models by family
Earnings-Based
Graham-Dodd C$0.1100 C$0.7400 C$1.03 63
Lynch FV C$0.2800 C$0.4100 C$0.5300 61
PEG = 1.0 C$0.2800 C$0.4100 C$0.5300 57
EPV C$0.1200 C$0.1600 C$0.2000 71
Multiples
P/E Multiple C$0.2600 C$0.3400 C$0.4300 63
P/S Multiple C$0.2000 C$0.2600 C$0.3300 58
P/B Multiple C$0.9300 C$1.24 C$1.54 55
EV/EBIT C$0.2200 C$0.3400 C$0.4500 65
EV/EBITDA C$0.6900 C$0.9500 C$1.22 67
EV/Revenue C$0.1300 C$0.2300 C$0.3400 52
Asset-Based
NCAV (Graham) C$0.1300 C$0.1900 C$0.2400 55
Economic Profit
Residual Income C$0.4600 C$0.4600 C$0.4700 76
ROIC Compounder C$0.1200 C$0.1600 C$0.2000 72
Growth Earnings
Growth-Adj P/E C$0.3700 C$0.5200 C$0.6800 67

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 38
How much profit the company makes from its sales and capital
Quality Growth 91
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 43
Debt, balance sheet and risk of trouble
Investment 60
Does it invest with discipline instead of growing at any price?
Low Volatility 56
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 24
Distance to the 52-week high, does not count
New shares 9
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+22.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.7%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+69.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−127.7% (2020) → 3.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Watch ROMJ, get fair value alerts →

Compare Rubicon Organics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside −9.1% · Above median
Profitability
Return on assets 1.6% · Below median
Net margin (12 months) −2.7% · Bottom 25%
Operating margin (12 months) 3.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) 23.1% · Top 25%
Balance sheet
Debt / equity 0.24× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.66× · Cheapest 25%
P/S (12 months) 0.45× · Cheapest 25%
EV/EBITDA 13.9× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)21 · sector 15
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)88 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs ROMJ
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs ROMJ
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs ROMJ
Haleon plc HLN $9.14 $8.61 −6% vs ROMJ
Merck KGaA MRK €148.75 €109.18 −27% vs ROMJ
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs ROMJ
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs ROMJ
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs ROMJ
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs ROMJ
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs ROMJ

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Rubicon Organics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Rubicon Organics Inc Fair Value". https://www.fairvalue-calculator.com/stock/ROMJ

Frequently asked questions

Is Rubicon Organics Inc (ROMJ) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of C$0.3910 versus a price of C$0.4300, about 9% lower (fairly valued).
What is the fair value of ROMJ?
Our model-based fair value for Rubicon Organics Inc is C$0.3910 (as of Nov 7, 2026), built from audited fundamentals. The current price: C$0.4300.
What is the quality score of ROMJ?
Rubicon Organics Inc has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rubicon Organics Inc (ROMJ)?
Our model-based price target is the fair value of C$0.3910 (as of Nov 7, 2026) from 14 valuation models. Cautious scenario C$0.3145, optimistic scenario C$0.3995. It is a calculation from audited fundamentals, not an analyst target.
What is the Rubicon Organics Inc stock forecast for 2026?
Our models put fair value at C$0.3910, about 9% lower versus a price of C$0.4300 (fairly valued). Cautious scenario C$0.3145, optimistic scenario C$0.3995. The calculation is refreshed regularly with new filings.
What is the revenue of Rubicon Organics Inc (ROMJ)?
Rubicon Organics Inc reported trailing-twelve-month revenue of about C$64.2M (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Rubicon Organics Inc (ROMJ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rubicon Organics Inc it is C$0.3910 per share (as of Nov 7, 2026), against a price of C$0.4300. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Rubicon Organics Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, ROMJ trades above its calculated fair value: price C$0.4300, fair value C$0.3910, a gap of about −9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ROMJ?
No. The price is what the market pays today (C$0.4300); the fair value is what the company's own numbers justify (C$0.3910). For Rubicon Organics Inc the two are C$0.0390 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rubicon Organics Inc worth?
The market values Rubicon Organics Inc at about C$28.9M (market capitalisation, as of Nov 7, 2026). Per share that is C$0.4300; our models calculate a fair value of C$0.3910 per share.
What do the bullish and bearish scenarios say about ROMJ?
Our models span a range for Rubicon Organics Inc: cautious scenario C$0.3145, base C$0.3910, optimistic C$0.3995 per share (as of Nov 7, 2026, price C$0.4300). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Rubicon Organics Inc (ROMJ)?
Balance-sheet figures for Rubicon Organics Inc (as of Nov 7, 2026): return on equity −4.1%, debt of 0.24 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is ROMJ from its 52-week high?
Rubicon Organics Inc trades at C$0.4300, about 27% below its 52-week high of C$0.5900 and 19% above the low of C$0.3600 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.3910 is for.
Which stocks are comparable to Rubicon Organics Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rubicon Organics Inc stock attractive at the current price?
The data as of Nov 7, 2026: price C$0.4300, calculated fair value C$0.3910 (−9%), Quality Score 36/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ROMJ calculated?
We run Rubicon Organics Inc through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of C$0.3910 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Rubicon Organics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rubicon Organics Inc (ROMJ)?
The closing price on Nov 6, 2026 was C$0.4300. Our model-based fair value is C$0.3910, about 9% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rubicon Organics Inc right now?
The price sits above even our optimistic bull case (C$0.3995). The favourable scenario is already priced in. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Rubicon Organics Inc

How large is the market capitalisation of Rubicon Organics Inc (ROMJ)?
The market capitalisation of Rubicon Organics Inc is C$28.9M (≈ $20.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rubicon Organics Inc (ROMJ)?
The price-to-sales ratio of Rubicon Organics Inc is 0.41 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rubicon Organics Inc (ROMJ)?
Earnings per share at Rubicon Organics Inc are C$−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Rubicon Organics Inc (ROMJ)?
The net margin of Rubicon Organics Inc is −2.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rubicon Organics Inc (ROMJ)?
The return on equity (ROE) of Rubicon Organics Inc is −4.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rubicon Organics Inc (ROMJ)?
On an EBIT basis the return on assets of Rubicon Organics Inc is −6.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rubicon Organics Inc (ROMJ)?
The operating margin of Rubicon Organics Inc is 3.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rubicon Organics Inc (ROMJ)?
Revenue at Rubicon Organics Inc is growing +23.1% versus a year earlier (3y avg +18.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Rubicon Organics Inc (ROMJ)?
Earnings per share at Rubicon Organics Inc are growing −41.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Rubicon Organics Inc (ROMJ) generate?
The free cash flow of Rubicon Organics Inc is −C$11.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Rubicon Organics Inc (ROMJ) carry?
The net debt of Rubicon Organics Inc is C$8.1M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Rubicon Organics Inc in the live analysis

One click puts Rubicon Organics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.